Group 1: Company Overview - The company focuses on fluorine fine chemicals, extending its business into pharmaceuticals, pesticides, and electronic chemicals, establishing a vertically integrated industrial chain from intermediates to APIs and formulations [1] - The company provides high-quality products and services to domestic and foreign clients [1] Group 2: Core Competencies - The company adheres to a growth strategy of "internal growth and external expansion," leveraging its fluorination technology, chiral enzyme catalysis, and green reaction technologies to extend its pharmaceutical and pesticide chains into high-value downstream areas [2] - The majority of the company's product varieties can be sold independently, demonstrating strong market adaptability and significant potential for product structure adjustment [2] - The company utilizes a production model that allows for the comprehensive use of by-products, reducing overall production costs [2] Group 3: Future Growth Points - Traditional products are expected to grow steadily, with multiple projects underway, including the Inner Mongolia Yongtai project and the Yongtai hand-in project, which are progressing smoothly [3] - The newly established pharmaceutical formulation production base has entered the commercial production phase, and the initial capacity of lithium battery materials is gradually being released, which will be key profit growth points over the next three years [3] Group 4: Development Strategy - The company aims to enhance existing production facilities, improve management levels, R&D capabilities, and environmental standards, while intensifying market development efforts, especially in deepening relationships with key customers [3] - The company plans to leverage its capital market advantages to achieve both internal growth and external development [3] Group 5: Pharmaceutical Sector Insights - The pharmaceutical sector is currently the highest revenue-generating segment and a key focus for future development, with plans to diversify into cardiovascular, diabetes, and antiviral fields [4] - The company aims to establish high-tech barriers in the formulation sector, promoting the development of a vertically integrated platform [4] Group 6: Technical Advantages - The company has developed a vertically integrated industrial chain from intermediates to formulations based on its unique fluorination technology and proprietary biocatalysis technology [5] - The company possesses advanced chiral enzyme catalysis technologies, significantly improving production efficiency and reducing costs [5] Group 7: Project Progress - The Inner Mongolia Yongtai project is expected to produce 18,715 tons of fine chemicals and 30,000 tons of potassium fluoride annually, with construction progressing smoothly since March 2020 [6] - The Yongtai hand-in project is currently preparing for trial production [5] Group 8: Market Outlook - The price increase of lithium hexafluorophosphate is expected to enhance the economic benefits of the electronic chemicals segment, as the company has improved production processes and cost control [6] - The dual fluorosulfonyl lithium product has a promising market outlook due to its high thermal stability and conductivity, despite currently being primarily imported [7]

Company Overview - Zhejiang Yongtai Technology Co., Ltd. was established in 1999 and listed in 2009, headquartered in Taizhou, Zhejiang [1] - The company focuses on fluorine fine chemicals, with main products categorized into pharmaceuticals, pesticides, lithium battery materials, and others [1] - Exports account for approximately 60%-70% of sales, with major clients including Merck, BASF, Bayer, and Syngenta [1] Financial Performance - In Q1 2021, the company achieved revenue of 853 million CNY, with a net profit of 86.13 million CNY, marking a year-on-year increase of 892.04% [1] Core Technologies - The company has developed four core technologies: 1. Directional fluorination technology, allowing fluorine atom introduction at any position on the benzene ring [2] 2. Advanced chiral enzyme catalysis technology, improving production efficiency and reducing costs [2] 3. Green reaction technology, with a patented product recognized nationally [2] 4. Co-production patent technology, enabling the utilization of by-products [2] Future Growth Points - The company has four key projects that will drive profit growth over the next 2-3 years, including: 1. An intermediate production base in Inner Mongolia, covering approximately 1,000 acres [3] 2. A pharmaceutical raw material project, with part of the first phase already in trial production [3] 3. An international pharmaceutical formulation project, with four ANDA applications approved by the FDA [3] 4. A lithium battery materials project, currently in capacity expansion [3] Development Strategy - The company aims to enhance existing production facilities, improve management and R&D capabilities, and deepen customer relationships to ensure sustainable growth [3] - Focus will be on the pharmaceutical and lithium battery materials sectors, leveraging core technologies for further development [3] Market Position and Competitive Advantages - The company has a strong quality control system and advanced production processes, allowing for effective cost control and product quality [4] - Current production capacity for lithium hexafluorophosphate is 2,000 tons per year, with plans to expand to 8,000 tons by the end of the year [4] - The dual fluorosulfonyl lithium product has a promising market outlook due to its high performance and stability [5]

Company Overview - Zhejiang Yongtai Technology Co., Ltd. was established in 1999 and listed in 2009, headquartered in Taizhou, Zhejiang Province [1] - The company focuses on fluorine fine chemicals, with main products categorized into pharmaceuticals, pesticides, lithium batteries, and other materials [1] - Approximately 60%-70% of sales are from exports, with major clients including Merck, BASF, Bayer, and Syngenta [1] Financial Performance - In Q1 2021, the company achieved revenue of 853 million CNY, with a net profit of 86.13 million CNY, marking a year-on-year growth of 892.04% [1] Industry Insights - The fluorochemical industry is divided into organic and inorganic fluorochemicals, with the company specializing in high-tech, high-value-added products [2] - The demand for fluorine fine chemicals is stable and has a certain degree of rigidity, making it resilient even in economic downturns [2] Core Technologies - The company has developed four core technologies: 1. Directional fluorination technology 2. Advanced chiral enzyme catalysis technology 3. Green reaction technology, with a patented product winning a national award in 2017 4. Co-production patent technology, allowing for the utilization of by-products [2] Future Growth Points - Four key projects are set to drive profit growth over the next 2-3 years, including intermediates, active pharmaceutical ingredients, formulations, and lithium battery materials [3] - The company is expanding its production capacity for intermediates and pharmaceutical raw materials, with several projects already in trial production [3] Strategic Development - The company aims to enhance existing production facilities, improve management and R&D capabilities, and deepen customer relationships to ensure sustainable growth [4] - Future focus areas include the pharmaceutical sector and lithium battery materials, leveraging core technologies for further development [4] Project Progress - The Inner Mongolia project is expected to produce 18,715 tons of fine chemicals and 30,000 tons of potassium fluoride annually, with trial production having commenced [3] - The company is also developing high-quality lithium hexafluorophosphate and other electrolyte additives, with plans for full coverage in the lithium battery supply chain [4][5] Market Outlook - The market for lithium hexafluorophosphate and lithium bis(fluorosulfonyl)imide is promising due to their high conductivity and stability, with significant future demand anticipated [5]

Company Overview - Zhejiang Yongtai Technology Co., Ltd. was established in 1999 and listed in 2009, headquartered in Taizhou, Zhejiang Province [1] - The company primarily produces fluorine fine chemicals, with main products categorized into three areas: pharmaceuticals, pesticides, and lithium battery materials [1] - The company reported a revenue of CNY 197.61 million in the first half of 2021, a year-on-year increase of 24.54%, and a net profit of CNY 17.74 million, up 61.16% year-on-year [1] Core Technologies - The company has developed four core technologies based on fluorination: 1. Directional fluorination technology, leading globally [2] 2. Advanced chiral enzyme catalysis technology, improving production efficiency and reducing costs [2] 3. Green reaction technology, with a national patent award for 2,4,5-trifluorobenzylacetic acid [2] 4. Co-production patent technology, allowing for the utilization of by-products [2] Lithium Battery Materials Business - The company produces high-quality lithium battery materials, including lithium hexafluorophosphate (LiPF6) and lithium bis(fluorosulfonyl)imide (LiFSI) [2] - The company has a 75% stake in Shaowu Yongtai High-tech Materials Co., Ltd., with a current production capacity of 2,000 tons/year for LiPF6, expected to expand to 8,000 tons/year by the end of 2021 [2] - A project for an annual production capacity of 20,000 tons of LiPF6 is underway, with preliminary assessments in progress [2] Production Expansion and Market Strategy - The company is expanding production for VC (vinylene carbonate) and FEC (fluoroethylene carbonate) due to increasing demand in the lithium battery sector [3] - The company is cautious about potential oversupply and price drops, conducting feasibility analyses based on conservative price forecasts [3] - The company aims to maintain competitive gross margins by optimizing product quality and costs while establishing long-term partnerships with major downstream clients [4] Future Outlook - The company has signed a 5.5-year agreement with CATL to ensure stable cooperation with leading enterprises [4] - The company is focused on becoming a core supplier of upstream materials for electrolytes, including LiPF6, LiFSI, VC, and FEC, while considering future adjustments to its industrial layout based on market demands [4]

Financial Performance - The company's revenue for the first half of 2021 was CNY 197,608.01 million, representing a year-on-year increase of 24.54% [3] - The net profit attributable to shareholders was CNY 9,529.94 million, a year-on-year decrease of 54.85%, while the net profit after deducting non-recurring gains and losses was CNY 17,735.57 million, up 61.16% year-on-year [3] - The overall gross margin improved from 28.47% last year to 31.64% this year [4] Business Segments - The sales structure for domestic and export markets was approximately 48.38% and 51.62%, respectively, indicating a shift from a previous 40% domestic to 60% export structure [4] - Revenue growth for different segments included: - Pharmaceutical products: 16.60% increase - Pesticides: 9.50% increase - Lithium battery materials: 196.88% increase [4] Lithium Battery Materials - The company has signed a material procurement agreement with CATL, with a minimum procurement quantity of 24,150 tons of lithium hexafluorophosphate from July 31, 2021, to December 31, 2026 [5] - Current production capacity for lithium hexafluorophosphate is approximately 2,000 tons/year, with an expansion project underway to reach 8,000 tons/year by the end of 2021 [5] - The company is also developing projects for producing 5,000 tons of VC and 3,000 tons of FEC [5] Market Dynamics - The demand for lithium battery materials, particularly lithium hexafluorophosphate, has significantly increased, leading to rising product prices [4] - The company aims to maintain competitive gross margins by optimizing product quality and reducing costs [7] - The company has established strategic partnerships with major clients to ensure stable demand and supply [7] Future Outlook - The company plans to accelerate capacity construction and expansion based on downstream market demand and collaboration with leading enterprises [6] - There is a focus on maintaining a unique competitive advantage through technological innovation and long-term partnerships with key customers [7] - The company is preparing for potential price fluctuations in raw materials by building strategic reserves and deepening cooperation with suppliers [8]

Company Overview - Zhejiang Yongtai Technology Co., Ltd. was established in 1999 and listed in 2009, headquartered in Taizhou, Zhejiang Province [1] - The company primarily produces fluorine fine chemicals, categorized into three main product lines: pharmaceuticals, pesticides, and lithium battery materials [1] Financial Performance - In the first three quarters of 2021, the company achieved operating revenue of CNY 3.273 billion, a year-on-year increase of 32.25% [2] - The overall gross profit margin was 34.56%, up by 6.61 percentage points year-on-year [2] - Net profit attributable to shareholders reached CNY 375 million, a year-on-year growth of 65.25% [2] - The net profit after deducting non-recurring gains and losses was CNY 411 million, a significant increase of 200.79% [2] Lithium Battery Materials Segment - Current production capacity for lithium hexafluorophosphate is approximately 2,000 tons/year, with actual monthly production exceeding 200 tons [2] - An additional 6,000 tons/year capacity is under construction, expected to be operational by the end of November to December 2021, bringing total capacity to 8,000 tons/year [2] - VC product production has been ramping up since August, with current output around 10-15 tons per day, aiming to stabilize at a design capacity of 5,000 tons/year [2] - Future capacity projections for lithium battery materials over the next three years include: - Lithium hexafluorophosphate: solid 8,000 tons/year, liquid 67,000 tons/year - Lithium bis(fluorosulfonyl)imide: solid 500 tons/year, liquid 67,000 tons/year - VC: 30,000 tons/year - FEC: 8,000 tons/year [2] Strategic Responses and Market Outlook - The company is addressing rising upstream raw material prices through strategic partnerships, process upgrades, and continuous production improvements [3] - Demand for lithium hexafluorophosphate is strong due to the rapid growth of the new energy vehicle sector, although there may be price risks as production capacity expands [3] - The contribution to profits from various business segments in the first half of 2021 was as follows: pharmaceuticals 32.43%, pesticides 18.72%, lithium battery materials 18.46%, and trade 30.01% [3] - The gross profit contributions were: pharmaceuticals 39.17%, pesticides 29.03%, lithium battery materials 58.81%, and trade 8.42% [3] Production and Technical Aspects - The production process for liquid lithium salts is more efficient than solid forms, reducing investment and production costs, although transportation costs may increase [4] - The company has established strong market responsiveness and equipment integration capabilities through years of collaboration with multinational enterprises [4] - The high price of VC is influenced by supply-demand dynamics, with current demand outpacing supply due to insufficient production capacity [4] - The decision to expand the production of lithium bis(fluorosulfonyl)imide is based on achieving technical goals related to cost reduction and by-product recycling [4]

Group 1: Financial Performance - In 2021, the revenue from pesticide products was 452.576 million RMB, accounting for 10.13% of total revenue [1] - In Q1 2022, the company achieved a revenue of 1.7373 billion RMB and a net profit of 389.7815 million RMB, with significant growth attributed to the lithium battery materials segment [2] - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares based on the total share capital of 876,566,295 shares as of December 31, 2021 [5] Group 2: Business Segments - The revenue breakdown for 2021 was as follows: pharmaceutical segment 26.14%, pesticide segment 10.13%, lithium battery and other materials segment 26.03%, and trading segment 36.81% [5] - The company is focusing on developing the pharmaceutical and lithium battery materials sectors, leveraging core technologies in fluorinated intermediates and chiral enzyme catalysis [5] Group 3: Production and Capacity - The company currently has a production capacity of 8,000 tons/year for lithium hexafluorophosphate, 5,000 tons/year for VC, and 3,000 tons/year for FEC [7] - The construction period for the lithium battery materials projects is approximately 1 year, with ongoing projects expected to be operational by the end of 2022 [7] Group 4: Market Strategy and Risk Management - The company is closely monitoring market price fluctuations and will implement cost-reduction strategies through technological improvements to maintain profitability [2] - The company emphasizes long-term development and value creation for investors, aiming to enhance profitability and strengthen investor relations [2] Group 5: Research and Development - Currently, the company has no plans for vaccine development or acquisition of lithium mines, focusing instead on upstream electrolyte and related materials [3] - The company is investing in the production capacity of sodium-ion battery materials, with a planned capacity of 250 tons [3]

Group 1: Company Overview - Zhejiang Yongtai Technology Co., Ltd. was established in 1999 and listed in 2009, with its headquarters located in Taizhou, Zhejiang Province. The main production bases are distributed across Zhejiang, Jiangsu, Shandong, Fujian, Guangdong, Chongqing, and Inner Mongolia [3]. - The company focuses on fine chemical products, primarily fluorine-containing chemicals, categorized into three main application areas: pharmaceuticals, pesticides, and lithium battery materials [3]. Group 2: Financial Performance - In 2021, the company achieved a net profit attributable to shareholders of 280.29 million yuan, representing a year-on-year increase of 133.56%. In Q1 2022, the net profit reached 389.78 million yuan, a growth of 434.67% compared to the same period last year [3]. - The pharmaceutical segment generated revenue of 1.169 billion yuan in 2021, showing a steady growth of 4.53% year-on-year [7]. Group 3: Lithium Battery Materials Segment - The lithium battery materials segment has recently achieved production capacities of 8,000 tons/year for lithium hexafluorophosphate, 5,000 tons/year for VC, 3,000 tons/year for FEC, and 900 tons/year for lithium bis(fluorosulfonyl)imide [4]. - The company plans to enhance research and development of lithium battery electrolyte and additive products to create a comprehensive one-stop procurement platform for customers [4]. Group 4: Pharmaceutical Segment Development - The company aims to expand its market share in high-value-added pharmaceutical products, leveraging its decades of experience in fluorine fine chemicals and fermentation technology [4]. - Current pharmaceutical products cover four major fields: endocrinology, cardiovascular, central nervous system, and digestive system, with several products already approved by the FDA for international sales [4]. Group 5: Strategic Initiatives and Challenges - The company is focused on both horizontal diversification and vertical integration in its lithium battery materials business, aiming to cover mainstream electrolyte materials comprehensively [5]. - To address potential price declines in lithium battery materials, the company has considered market price fluctuations in its investment projects and aims to reduce production costs through technological improvements [6].

Financial Performance - The company's revenue for Q3 2022 reached ¥1,564,332,473.63, representing a year-on-year increase of 20.64%[5] - Net profit attributable to shareholders decreased by 79.24% to ¥58,142,265.87, primarily due to a decline in market prices for lithium battery materials[8] - The net profit after deducting non-recurring gains and losses was ¥43,741,991.34, down 81.27% compared to the same period last year[5] - Total operating revenue for the third quarter of 2022 reached CNY 4,881,231,011.48, a significant increase from CNY 3,272,769,509.20 in the same period last year, representing a growth of approximately 49.1%[24] - Operating profit for the third quarter was CNY 796,106,530.40, up from CNY 525,718,348.28, indicating a year-over-year increase of about 51.4%[27] - Net profit attributable to shareholders of the parent company was CNY 551,746,368.93, compared to CNY 375,434,124.49 in the previous year, reflecting a growth of approximately 46.8%[27] - The company reported a comprehensive income total of CNY 649,712,260.27, compared to CNY 428,667,544.66 in the same quarter last year, indicating a growth of approximately 51.5%[30] - Basic and diluted earnings per share for the quarter were both CNY 0.63, up from CNY 0.43 in the previous year, reflecting a growth of approximately 46.5%[30] Assets and Liabilities - The company's total assets increased by 14.92% to ¥11,175,124,506.30 compared to the end of the previous year[5] - The total liabilities increased to CNY 6,876,034,034.46 from CNY 5,989,766,706.20, marking an increase of about 14.8%[23] - The company's total equity rose to CNY 4,299,090,471.84, up from CNY 3,734,658,032.00, which is an increase of approximately 15.1%[23] - The company's total current assets as of September 30, 2022, amounted to CNY 4,282,142,651.46, an increase from CNY 3,591,276,563.16 at the beginning of the year[21] - The total assets of the company reached CNY 11,175,124,506.30, compared to CNY 9,724,424,738.20 at the beginning of the year[21] - Short-term borrowings increased to CNY 2,053,222,931.10 from CNY 1,661,850,755.70[21] - The company's inventory as of September 30, 2022, was CNY 1,429,862,665.20, up from CNY 1,202,286,819.15 at the beginning of the year[21] - The company reported a significant increase in accounts receivable, which rose to CNY 1,095,979,682.81 from CNY 670,211,256.08[21] - The company's contract liabilities amounted to CNY 888,420,296.83, compared to CNY 706,748,543.92 in the previous year, indicating an increase of approximately 25.7%[23] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥671,723,013.71, an increase of 44.53% year-on-year[5] - The net cash flow from operating activities increased by 44.53% due to higher sales and cash recovery[14] - Operating cash flow for the period reached ¥671,723,013.71, an increase of 44.5% compared to ¥464,771,345.32 in the previous period[31] - Total cash inflow from investment activities was ¥303,486,474.96, significantly higher than ¥128,462,547.64 in the previous period[34] - Net cash flow from investment activities was -¥879,853,181.22, worsening from -¥601,273,911.82 in the previous period[34] - Cash inflow from financing activities totaled ¥1,904,116,087.78, up from ¥1,675,619,364.02 in the previous period[34] - Net cash flow from financing activities improved to ¥245,679,460.27 from ¥105,364,734.10 in the previous period[34] - The ending balance of cash and cash equivalents increased to ¥426,035,702.72, compared to ¥253,730,812.22 in the previous period[34] - Cash received from sales of goods and services was ¥3,095,578,703.38, up from ¥2,724,738,671.25 in the previous period[31] - Cash paid for purchasing goods and services decreased to ¥1,687,030,874.03 from ¥1,920,289,914.95 in the previous period[31] - Cash received from tax refunds was ¥165,614,408.46, slightly down from ¥168,981,786.00 in the previous period[31] - Cash paid for employee compensation increased to ¥347,144,046.14 from ¥285,304,911.03 in the previous period[31] Research and Development - The company reported a significant increase in research and development expenses by 40.15% due to increased investment in R&D activities[13] - Research and development expenses for the quarter were CNY 133,202,506.49, compared to CNY 95,041,239.31 in the previous year, showing an increase of about 40.1%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 152,739, with the largest shareholder holding 16.46%[15] - Wang Yingmei, the largest shareholder, holds 144,248,400 shares, with 41,658,000 shares pledged[15] Market Strategy - The company plans to expand its market presence in the lithium battery materials sector, responding to the overall growth trend in the new energy industry[8]

Financial Performance - The company reported a total revenue of 1.2 billion CNY for the first half of 2022, representing a year-on-year increase of 15%[21]. - The net profit attributable to shareholders was 200 million CNY, up 10% compared to the same period last year[21]. - The company's operating revenue for the first half of 2022 was ¥3,316,898,537.85, representing a 67.85% increase compared to ¥1,976,080,060.72 in the same period last year[28]. - Net profit attributable to shareholders was ¥493,604,103.06, a significant increase of 417.95% from ¥95,299,431.31 in the previous year[28]. - The basic earnings per share rose to ¥0.56, up 409.09% from ¥0.11 in the same period last year[28]. - The company reported a net cash flow from operating activities of ¥467,447,623.09, reflecting a 259.33% increase from ¥130,087,359.63 in the previous year[28]. - The company has set a revenue target of 2.5 billion CNY for the full year 2022, which would require a growth rate of approximately 10% in the second half[21]. - The trade segment's revenue grew by 103.39% to ¥1,206,282,024.52, indicating strong performance in this area[63]. Investment and R&D - The company plans to invest 300 million CNY in R&D for new product development and technological advancements in the upcoming year[21]. - Research and development expenses increased by 50.25% to ¥85,848,557.06, driven by increased investment in developing proprietary products[60]. - The company has applied for a total of 165 invention patents, with 119 already granted, showcasing its strong R&D capabilities[52]. - The company is committed to innovation in fluorine-based pharmaceuticals, pesticides, and new energy materials, providing customized R&D and production services[41]. Market Expansion and Strategy - Market expansion efforts have led to a 25% increase in sales in international markets, contributing significantly to overall revenue growth[21]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[21]. - The pharmaceutical sector is focusing on vertical integration from intermediates to APIs and formulations, aiming to enhance profitability and expand international markets[39]. - The agricultural chemicals segment is building a vertically integrated supply chain, leveraging technology to strengthen its market position amid increasing competition[40]. - The company has established a vertical integration strategy, extending its product chain from intermediates to high-value-added raw materials and formulations[51]. Environmental Commitment - The company is committed to sustainability and has initiated projects aimed at reducing its carbon footprint by 15% over the next three years[21]. - The company has implemented wastewater treatment facilities with a capacity of 600 tons/day and 1280 tons/day for its two plants, respectively[116]. - The company operates air pollution control facilities with a total capacity of 70,000 m³/h, utilizing advanced treatment processes[116]. - The total emissions for COD were reported at 33.39 mg/L, with ammonia nitrogen at 0.608 mg/L, and VOCs at 6.63 mg/m³, all within regulatory limits[111]. - The company has not exceeded the approved emission limits for any pollutants during the reporting period[111]. - Yongtai has implemented measures to reduce carbon emissions, although specific effects are not detailed[128]. Risks and Challenges - The company faces risks related to supply chain disruptions and regulatory changes, which are detailed in the risk management section of the report[5]. - The company is exposed to industry and market competition risks, necessitating continuous improvement in management mechanisms and technological innovation[94]. - Raw material price fluctuations pose a risk to the company's production and operating costs, as raw materials constitute a significant portion of the cost structure[95]. - The company is exposed to foreign exchange rate fluctuation risks, particularly in its export business, which is primarily settled in USD[101]. - The company faces macroeconomic risks due to the complex international economic situation, which may impact domestic economic recovery and overall business operations[93]. Corporate Governance and Shareholder Information - The company emphasizes social responsibility and actively contributes to local economic development and charitable causes[128]. - Yongtai maintains a robust corporate governance structure to protect the rights of shareholders and ensure transparent information disclosure[129]. - The company has not engaged in any related party transactions during the reporting period[153]. - The total number of shares outstanding is 876,566,295, with 22.98% held as limited shares and 77.02% as unrestricted shares[181]. - The number of shareholders holding more than 5% of shares includes Wang Yingmei with 17.69% and He Renbao with 12.71%[185]. Operational Highlights - The company has established a comprehensive EHS management system and has not experienced any production safety accidents during the reporting period[137]. - The company has not reported any significant litigation or arbitration cases that would impact its operations[148]. - The company did not report any significant changes in user data or performance metrics during the reporting period[161]. - The company has not announced any new product developments or market expansion strategies in the reporting period[109].